MRM Health secured $64 million in Series B funding in September 2025 to advance its pipeline of microbiome-based biotherapeutic products aimed at inflammatory diseases, notably inflammatory bowel disease (IBD) such as ulcerative colitis.345
The lead product, MH002, is an advanced live biotherapeutic product (LBP) consisting of a rationally designed consortium of bacteria targeted for mild-to-moderate ulcerative colitis. It has shown positive efficacy and safety in Phase IIa studies and will use this funding to complete Phase IIb trials.345
This Series B round was led by Biocodex, with other investors including ATHOS, BNP Paribas Fortis Private Equity, SFPIM, OMX Europe Venture Fund, Ackermans & van Haaren, VIB, and Qbic II.345
In addition to MH002, the funding is expected to advance two more programs aiming for IND (Investigational New Drug) approval in areas of inflammation and immune-oncology.45
MRM Health has formed a strategic partnership with Biocodex, providing not only funding but also non-dilutive support and manufacturing capability for ongoing and future clinical trials.45
Treeline also gathered $200 million as part of the Fierce Biotech Fundraising Tracker 2025, indicating robust investor interest in innovative biotech ventures this year.
Sources:
3. https://www.pharmaceutical-technology.com/news/mrm-health-pipeline/
4. https://trial.medpath.com/news/730019587a7c1a95/mrm-health-secures-eur55-million-series-b-to-advance-microbiome-based-therapeutics-for-inflammatory-diseases
5. https://european-biotechnology.com/latest-news/microbiome-play-mrm-health-nv-raises-e55m-in-series-b/